Prevalence of overt and occult hepatitis B virus infections among 135 haemodialysis patients attending a haemodialysis centre at Al-Nasiriyah city, Iraq

  • Muslim Dhahr Musa Mail Department of Community Health, Al-Nasiriyah Technical Institute/Southern Technical University, Al-Nasiriyah, Thi-Qar, Iraq
  • Hekmat Kadhum Ateya Department of Microbiology, School of Veterinary Medicine, Thi-Qar University, Al-Nasiriyah, Thi-Qar, Iraq
Keywords:
Haemodialysis;, Hepatitis B virus infection;, Serological;, Real-time polymerase chain reaction

Abstract

Background and Objectives: The prevalence of Hepatitis B virus (HBV) infection among haemodialysis (HD) patients has been well documented. In addition to overt infection, occult Hepatitis B infection exists in which a patient who is diagnosed seronegative for Hepatitis B surface antigen (HBsAg) shows positive HBV-DNA on using more accurate molecular methods. This study aims to determine the prevalence of overt and occult HBV infection among the HD patients who had attended Al-Nasiriyah dialysis centre during a two-month period.
Materials and Methods: Serological qualitative detection of HBsAg by rapid test (strips), enzyme immunoassay (EIA, HBsAg) and molecular (real-time polymerase chain reaction (real-time PCR)) was conducted for quantitative detection of HBV in HD patients’ serum.
Results: The prevalence of overt HBV infection among HD patients was 3.7%. The viral load of HBV positive patients was ranging from 5.85 × 101 to 2.16 × 106 copies/ml of serum with median (7.4 × 105 copies/ml). Occult Hepatitis B was not detected in any of the seronegative HD patients (0%). Overt infection was found more in males (80%) than females (20%) (P<0.05). Similarly, infection was found to be higher among patients who had blood transfusions (80%) than those who had not (20%) with statistical significant p<0.05. Although not statistically significant, the mean duration of HD was higher among HBV positive HD patients (17.6) than HBV negative HD patients (14.3). A dual infection of HBV and HCV was not detected in this study.
Conclusion: Nosocomial transmissions at HD centres and blood transfusion are important risk factors. Besides serological screening, real-time PCR offers a safeguard against the spread of overt and occult HBV infection and determines the viral load of the positive patients.

References

1. Flichman DM, Blejer JL, Livellara BI, Re VE, Bartoli S, Bustos JA, et al. Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. BMC Infect Dis 2014;14:218.
2. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton) 2010;15: 137-145.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
4. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: Changing the epidemiology. Hemodial Int 2008;12:378-382.
5. Fontenele AMM, Filho NS, Ferreira ASP. Occult hepatitis B in patients on hemodialysis: a review. Ann Hepatol 2013;12:359-363.
6. Kalantari H, Ferdowsi F, Yaran M. Prevalence of occult hepatitis B virus infection in hemodialysis patients in Isfahan, Iran. Adv Biomed Res 2016; 5:151.
7. Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations. Arab J Nephrol Transplant 2011;4:35-47.
8. Ismail H, Soliman M, Ismail N. Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection. Pathol Lab Med Int 2010:2:113-120.
9. Ayatollahi J, Sharifyazdi M, Shahcheraghi SH, Jahanabadi S, Hemayati R, Vakili M. The prevalence of occult hepatitis B virus in the hemodialysis patients in Yazd, Iran. Acta Med Iran 2016;54:784-787.
10. Saijo T, Joki N, Inishi Y, Muto M, Saijo M, Hase H. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial 2015;19:125-130.
11. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult Hepatitis B infection in chronic hemodialysis patients: current concepts and strategy. Hepat Mon 2010; 10: 199-204.
12. Otedo AEO, Mc’Ligeyo SO, Okoth FA, Kayima JK. Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country. S Afr Med J 2003;93:380-384.
13. Alibakhshikenari M. Prevalence of Hepatitis B and C viruse’s infections among hemodialysis patients in Tehran, Iran. Biomed J Sci & Tech Res 2018;11:8359-8363.
14. Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of Hepatitis B surface antigenemia (HBsAg) in hemodialysis Pateints. Arch Intern Med 1979;139:178-180.
15. Torbenson M, Thomas DL. Occult hepatitis B Michael. Lancet Infect Dis 2002;2:479-486.
16. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657.
17. Aghakhani A, Banifazl M, Velayati AA, Eslamifar A, Ramezani A. Occult Hepatitis B virus infection in hemodialysis patients: A concept for consideration. Ther Apher Dial 2012;16:328-333.
18. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunol 2013; 35: 39-52.
19. Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: A multicenter study. Ther Apher Dial 2010;14:349-353.
20. Minuk GY, Dong FS, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004;40:1072-1077.
21. Nagakawa O, Miyatomi Y, Shigeta Y, Inayama E, Murakami K, Sakai T, et al. Occult hepatitis B virus infection in Japanese chronic hemodialysis patients. Ther Apher Dial 2013;17:289-292.
22. Abass YA, Khawam R, Kareem AA. Epidemiology of Hepatitis HBV and HCV at Thi-Qar. QMJ 2008;4:160-171.
23. Tarky AA, Akram W, Al-naaimi A, Omer A. Epidemiology of viral hepatitis B and C in Iraq: a national survey 2005-2006. Zanco J Med Sci 2013;17:370-380.
24. Ibrahim NMR, Sidiq Z, Saleem M, Hussein NR. The prevalence of HIV, HCV, and HBV Among hemodialysis patients attending Duhok hemodialysis center. 2017;5 (1); e63246.
25. Shihab SS, Al-Hmudi HA, Al-Edani HS, Mahdi KH. Viral hepatitis infections in Basrah haemodialysis unit: Serological diagnosis and viral loading. Eur J Exp Biol 2014;4:106-112.
26. Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, Amini A, Rezaee SAR. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl 2009;20:681-684.
27. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 2012;12:265.
28. Yoo JH, Hwang SG, Yang DH, Son MS, Kwon C, Ko KH, et al. Prevalence of occult Hepatitis B virus infection in hemodialysis patients Jeong. Korean J Gastroenterol 2013;61:209-214.
29. Al–Hamdani AH, Al-Rawy SK, Khamees HA. Retrospective seroprevalence study of Hepatitis B and C in Iraqi population at Baghdad: A hospital based study. Iraqi J Comm Med 2012;25:186-190.
30. Mahdavimazdeh M, Hosseini-Moghaddam SM, Alavian SM, Yahyazadeh H. Hepatitis B infection in Hemodialysis patients in Tehran province, Iran. Hepat Mon 2009;9:206-210.
31. Zabadi HA, Rahal H, Fuqaha R. Hepatitis B and C prevalence among hemodialysis patients in the West Bank hospitals, Palestine. BMC Infect Dis 2015;16:41.
32. Al Hijazat M, Ajlouni YM. Hepatitis B infection among patients receiving chronic hemo- dialysis at the Royal Medical Services in Jordan. Saudi J Kidney Dis Transpl 2008;19:260-267.
33. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006;28:729-735.
34. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003;63:2222-2229.
35. Altindiş M, Uslan I, Cetinkaya Z, Yüksel S, Ciftçi IH, Demirtürk N, et al. Investigation of hemodialysis patients in terms of the presence of occult hepatitis B. Mikrobiyol Bul 2007;41:227‑233.
36. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341-1347.
37. Goral V, Ozkul H, Tekes S, Sit D, Kadiroglu AK. Prevalence of occult HBV infection in hemodialysis patients with chronic HCV. World J Gastroenterol 2006;12:3420-3424.
38. Abu MA, Makarem E, Hamid MA, Aleem AA, Ali A, Shatat M, et al. Prevalence of occult Hepatitis B virus infection in hemodialysis patients from Egypt with or without Hepatitis C virus infection. Hepat Mon 2012;12:253-258.
39. Athbi HA. Prevalence and risk factors for Hepatitis C and B viruses infection among Hemodialysis patients in Holy Karbala, Iraq. KUFA J Nurs Sci 2015;5:1-8.
40. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006;101:689-692.
Published
2020-10-31
How to Cite
1.
Musa M, Ateya H. Prevalence of overt and occult hepatitis B virus infections among 135 haemodialysis patients attending a haemodialysis centre at Al-Nasiriyah city, Iraq. Iran J Microbiol. 12(5):475-482.
Section
Original Article(s)